跳至主導覽 跳至搜尋 跳過主要內容

Toward transplantation tolerance with adipose tissue-derived therapeutics

  • Hui Yun Cheng*
  • , Madonna Rica Anggelia
  • , Cheng Hung Lin
  • , Fu Chan Wei
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Chang Gung University

研究成果: 期刊稿件文獻綜述同行評審

12 引文 斯高帕斯(Scopus)

摘要

Solid organ and composite tissue allotransplanation have been widely applied to treat end-stage organ failure and massive tissue defects, respectively. Currently there are a lot of research endeavors focusing on induction of transplantation tolerance, to relieve the burden derived from long-term immunosuppressant uptake. The mesenchymal stromal cells (MSCs) have been demonstrated with potent immunomodulatory capacities and applied as promising cellular therapeutics to promote allograft survival and induce tolerance. As a rich source of adult MSCs, adipose tissue provides additional advantages of easy accessibility and good safety profile. In recent years, the stromal vascular fraction (SVF) isolated from adipose tissues following enzymatic or mechanical processing without in vitro culture and expansion has demonstrated immunomodulatory and proangiogenic properties. Furthermore, the secretome of AD-MSCs has been utilized in transplantation field as a potential “cell-free” therapeutics. This article reviews recent studies that employ these adipose-derived therapeutics, including AD-MSCs, SVF, and secretome, in various aspects of organ and tissue allotransplantation. Most reports validate their efficacies in prolonging allograft survival. Specifically, the SVF and secretome have performed well for graft preservation and pretreatment, potentially through their proangiogenic and antioxidative capacities. In contrast, AD-MSCs were suitable for peri-transplantation immunosuppression. The proper combination of AD-MSCs, lymphodepletion and conventional immunosuppressants could consistently induce donor-specific tolerance to vascularized composite allotransplants (VCA). For each type of transplantation, optimizing the choice of therapeutics, timing, dose, and frequency of administration may be required. Future progress in the application of adipose-derived therapeutics to induce transplantation tolerance will be further benefited by continued research into their mechanisms of action and the development of standardized protocols for isolation methodologies, cell culture, and efficacy evaluation.

原文英語
文章編號1111813
頁(從 - 到)1111813
期刊Frontiers in Immunology
14
DOIs
出版狀態已出版 - 2023
對外發佈

文獻附註

Copyright © 2023 Cheng, Anggelia, Lin and Wei.

指紋

深入研究「Toward transplantation tolerance with adipose tissue-derived therapeutics」主題。共同形成了獨特的指紋。

引用此